Lundbeck appoints new commercial senior vice president and vice president
H. Lundbeck A/S (Lundbeck) has appointed Andreas Eggert as senior vice president for global product strategy with responsibility for Lundbeck's launch of new medicines. Since joining Lundbeck in 2010, Andreas Eggert has driven marketing strategy development and execution and the close collaboration between business areas and stakeholders that is crucial to bringing new medicines to market.
In this role, Andreas Eggert has successfully strengthened and developed Lundbeck's strategic marketing at a time when Lundbeck is poised to launch several new medicines, including the antidepressant vortioxetine; Selincro for the treatment of alcohol dependence; and the once-monthly formulation of aripiprazole for the treatment of schizophrenia.
Andreas Eggert has been a member of Lundbeck's corporate management group since September 2011 and has reported directly to president and CEO Ulf Wiinberg since May 2012.
Klaus Abel has been appointed vice president with responsibility for commercialisation of medicines from Lundbeck's partnership with the Japanese company Otsuka Pharmaceuticals. Lundbeck and Otsuka entered one of the most broad-reaching partnerships ever established in the fields of psychiatry and neurology in November 2011, and are collaborating on the development of up to five innovative medicines for the treatment of various brain disorders. Klaus Abel will have special focus on collaborative development and commercialisation of two medicines: once-monthly aripiprazole formulation for the treatment of schizophrenia, and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.
Klaus Abel joined Lundbeck in 2000 and has held positions in a variety of different areas, including leading roles in Lundbeck's business development department, managing director of Lundbeck's affiliate in Australia and New Zealand, and most recently executive director with commercial responsibility for established Lundbeck products such as Cipralex, Ebixa and Azilect.
Klaus Abel reports to senior vice president Andreas Eggert.
Contacts
Mads Kronborg, Media Relations Manager Simon Augustesen, Media Relations
Phone (direct): +45 36 43 28 51 Phone (direct): +45 36 43 49 80
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.
